Invivyd (IVVD) Competitors $0.73 +0.04 (+5.52%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.74 +0.00 (+0.51%) As of 08/1/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. ATXS, TNXP, AURA, PRTA, CADL, GLUE, RNAC, FHTX, RCKT, and INBXShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Astria Therapeutics (ATXS), Tonix Pharmaceuticals (TNXP), Aura Biosciences (AURA), Prothena (PRTA), Candel Therapeutics (CADL), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors Astria Therapeutics Tonix Pharmaceuticals Aura Biosciences Prothena Candel Therapeutics Monte Rosa Therapeutics Cartesian Therapeutics Foghorn Therapeutics Rocket Pharmaceuticals Inhibrx Biosciences Astria Therapeutics (NASDAQ:ATXS) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Which has more volatility & risk, ATXS or IVVD? Astria Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Is ATXS or IVVD more profitable? Astria Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -389.01%. Astria Therapeutics' return on equity of -47.18% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -47.18% -31.26% Invivyd -389.01%-165.24%-99.71% Does the media refer more to ATXS or IVVD? In the previous week, Astria Therapeutics had 3 more articles in the media than Invivyd. MarketBeat recorded 3 mentions for Astria Therapeutics and 0 mentions for Invivyd. Astria Therapeutics' average media sentiment score of 0.82 beat Invivyd's score of 0.00 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Astria Therapeutics Positive Invivyd Neutral Do insiders & institutionals believe in ATXS or IVVD? 99.0% of Astria Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 4.5% of Astria Therapeutics shares are owned by insiders. Comparatively, 25.4% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, ATXS or IVVD? Astria Therapeutics has higher earnings, but lower revenue than Invivyd. Astria Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$94.26M-$1.87-3.51Invivyd$36.69M2.39-$169.93M-$1.20-0.61 Do analysts prefer ATXS or IVVD? Astria Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 342.07%. Invivyd has a consensus target price of $5.85, indicating a potential upside of 698.85%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Astria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryAstria Therapeutics beats Invivyd on 10 of the 16 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.25M$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.6117.7428.8323.83Price / Sales2.39179.21372.0766.02Price / CashN/A41.9535.4557.96Price / Book1.318.508.275.54Net Income-$169.93M-$55.06M$3.25B$259.28M7 Day Performance-6.71%-3.99%-3.73%-4.68%1 Month Performance1.29%9.58%4.29%4.36%1 Year Performance-35.76%6.70%25.87%17.88% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.008 of 5 stars$0.73+5.5%$5.85+698.9%-38.7%$83.25M$36.69M-0.61100ATXSAstria Therapeutics2.4034 of 5 stars$6.63-0.3%$30.00+352.5%-41.4%$375.29MN/A-3.5530News CoveragePositive NewsTNXPTonix Pharmaceuticals3.4312 of 5 stars$47.30-4.9%$70.00+48.0%-24.9%$365.84M$10.09M-0.0250Analyst RevisionGap DownAURAAura Biosciences1.556 of 5 stars$6.99-3.3%$22.00+214.7%-31.6%$363.44MN/A-3.6850Gap DownPRTAProthena3.2473 of 5 stars$6.87+2.8%$31.50+358.5%-69.5%$359.56M$135.16M-3.30130News CoverageUpcoming EarningsCADLCandel Therapeutics2.1899 of 5 stars$6.86-2.3%$22.00+220.7%+13.5%$351.72M$120K-5.1260Gap DownGLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.55-2.1%$15.33+176.3%+9.6%$348.76M$75.62M69.3890RNACCartesian Therapeutics1.4107 of 5 stars$13.70+2.8%$40.00+192.0%-20.3%$345.97M$38.91M-0.2664Upcoming EarningsFHTXFoghorn Therapeutics2.4956 of 5 stars$6.50+5.0%$12.13+86.5%-23.3%$345.04M$22.60M-4.78120Upcoming EarningsGap DownRCKTRocket Pharmaceuticals4.8355 of 5 stars$3.11-1.0%$17.87+474.5%-86.5%$335.31MN/A-1.18240Trending NewsUpcoming EarningsINBXInhibrx Biosciences1.3548 of 5 stars$24.57+6.5%N/A+48.2%$334.10M$200K0.21166 Related Companies and Tools Related Companies ATXS Competitors TNXP Competitors AURA Competitors PRTA Competitors CADL Competitors GLUE Competitors RNAC Competitors FHTX Competitors RCKT Competitors INBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVVD Stock Alerts